J0457
J0457 – Injection, aztreonam, 100 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 11 NDCs crosswalked per 100 MG $2.271/unit ASP+6%
📋 J0457 summary
J0457 is a HCPCS Level II J-code used to bill aztreonam, 100 mg, billed per 100 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J0457: Azactam*, Azactam, Aztreonam
Code J0457
Billing unit 100 MG Payment limit $2.271/unit NDC-Crosswalk 11
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ0457
DescriptorInjection, aztreonam, 100 mg
Billing unit100 MG
Payment limit / unit$2.271
Est. ASP / unit$2.142 est.
Mapped NDCs11
Data periodQ3 2026
Last updated2026-08-20
💊 About Aztreonam Injection DRUG GUIDE
Azactam (aztreonam for injection) is used to treat infections caused by susceptible gram-negative bacteria.
It is approved for urinary tract infections (including kidney infections and bladder infections), lower respiratory tract infections (including pneumonia), bloodstream infections (septicemia), skin and skin-structure infections (including those related to wounds, ulcers, and burns), intra-abdominal infections (including peritonitis), and gynecologic infections (including endometritis and pelvic cellulitis).Azactam is also used alongside surgery to manage infections such as abscesses and infections involving perforated organs.
In seriously ill patients who may also have gram-positive bacterial infections, it is often started together with another antibiotic that covers those bacteria.
When anaerobic bacteria (bacteria that don't need oxygen) are also suspected, an anti-anaerobic antibiotic is added as well.
Clinical overview from our editorial drug guide for Aztreonam Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$2.271
Est. ASP / unit
$2.142 est.
Est. after 2% sequester
$2.226
HCPCS dosage
100 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, aztreonam, 100 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeP — Payment change
Effective date2024-01-01
Date added2023-07-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J0457 = 100 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J0457 WITH EST. MEDICARE PAY
11 NDCs map to J0457. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($2.271/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00003-2560-16 | AZACTAM AZTREONAM 1 g/1 INJECTION, POWDER, FOR SOLUTION | E.R. | 10 VIAL, SINGLE-DOSE in 1 CARTON (0003-256... | 1 g/1 | 100 | $227.10 | — | ● Active | CMS + PDAC |
| 00003-2570-16 | AZACTAM AZTREONAM 2 g/1 INJECTION, POWDER, FOR SOLUTION | E.R. | 10 VIAL, SINGLE-DOSE in 1 CARTON (0003-257... | 2 g/1 | 200 | $454.20 | — | ● Active | CMS + PDAC |
| 00409-0829-01 | Aztreonam 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Hospira, | 10 VIAL, SINGLE-DOSE in 1 CARTON (0409-082... | 1 g/1 | 100 | $227.10 | — | ● Active | CMS + PDAC |
| 00409-0830-01 | Aztreonam 2 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Hospira, | 10 VIAL, SINGLE-DOSE in 1 CARTON (0409-083... | 2 g/1 | 200 | $454.20 | — | ● Active | CMS + PDAC |
| 50090-7494-00 | AZACTAM AZTREONAM 1 g/1 INJECTION, POWDER, FOR SOLUTION | A-S | 10 VIAL, SINGLE-DOSE in 1 CARTON (50090-74... | 1 g/1 | 100 | $227.10 | — | ● Active | CMS ASP |
| 63323-0401-20 | Aztreonam 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 10 VIAL in 1 TRAY (63323-401-20) / 1 INJE... | 1 g/1 | 100 | $227.10 | — | ● Active | CMS + PDAC |
| 63323-0401-24 | Aztreonam 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 10 VIAL in 1 TRAY (63323-401-24) / 1 INJE... | 1 g/1 | 100 | $227.10 | — | ● Active | CMS + PDAC |
| 63323-0401-26 | Aztreonam 1 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 10 VIAL in 1 TRAY (63323-401-26) / 1 INJE... | 1 g/1 | 100 | $227.10 | — | ● Active | CMS + PDAC |
| 63323-0402-20 | Aztreonam 2 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 10 VIAL in 1 TRAY (63323-402-20) / 1 INJE... | 2 g/1 | 200 | $454.20 | — | ● Active | CMS + PDAC |
| 63323-0402-24 | Aztreonam 2 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 10 VIAL in 1 TRAY (63323-402-24) / 1 INJE... | 2 g/1 | 200 | $454.20 | — | ● Active | CMS + PDAC |
| 63323-0402-30 | Aztreonam 2 g/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Fresenius | 10 VIAL in 1 TRAY (63323-402-30) / 1 INJE... | 2 g/1 | 200 | $454.20 | — | ● Active | CMS + PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$2K
Claims
42
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$48.09
Trend by period
Where J0457 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #746 of 824
#741
DEXTROSE 5%-0.9% NAC... J7042
$2.4K
#742
PELLOGRAFT, PER SQ C... Q4320
$2.2K
#743
HYPERRHO* J2790
$2.2K
#744
POLOCAINE-MPF* J0670
$2.1K
#745
NAFCILLIN SODIUM J2290
$2K
#746
AZACTAM* J0457
$2K
#747
FLUPHENAZINE DECANOA... J2680
$1.9K
#748
ATIVAN* J2060
$1.8K
#749
ACETAMINOPHEN(J0136) J0136
$1.7K
#750
BICILLIN C-R J0558
$1.7K
#751
RECOMBIVAX HB 90743
$1.7K
Total claims — #708 of 824
#703
MYLOTARG J9203
45
#704
PREMARIN J1410
44
#705
DERM-MAXX, PER SQ CM... Q4238
44
#706
ABILIFY ASIMTUFII J0402
43
#707
COMPLETE AA, PER SQ... Q4303
43
#708
AZACTAM* J0457
42
#709
BERINERT J0597
42
#710
CALCIUM GLUCONATE-NA... J0613
42
#711
PENICILLIN G POTASSI... J2540
42
#712
BIOVANCE 1 SQUARE CM... Q4154
42
#713
VITOGRAFT, PER SQ CM... Q4317
42
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $2K | — | 42 | — | $48.09 |
| 2025 (Q1-Q4) | $41.3K | 47 | 425 | $879.75 | $97.29 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$42K
Medicare paid
$32.8K
Submitted services
60,277
Denial rate
70.8%
Allowed / service
$2.38
Submitted charges
$783.4K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
📊 What bills under J0457
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
11 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J0457 billing FAQ
What is HCPCS code J0457?
J0457 is a HCPCS Level II J-code used to bill Injection, aztreonam, 100 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0457?
One unit of J0457 represents 100 MG. Report the number of units equal to the dose administered divided by 100 MG.
How many units of J0457 should I bill?
Divide the dose administered by the code's unit size (100 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0457?
The Medicare Part B payment limit is $2.271 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $2.226 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0457?
11 NDCs currently map to J0457 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0457 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.